Targeting angiogenesis in advanced cervical cancer

被引：29
作者：
Eskander, Ramez N. [2 ]
Tewari, Krishnansu S. [1 ]
机构：
[1] Univ Calif Irvine, Div Gynecol Oncol, Dept Obstet & Gynecol, Orange, CA 92868 USA
[2] Univ Calif Irvine, Div Gynecol Oncol, Dept Obstet & Gynecol, Med Ctr, Orange, CA 92868 USA
来源：
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2014年 / 6卷 / 06期
关键词：
angiogenesis; bevacizumab; cervical cancer; ENDOTHELIAL GROWTH-FACTOR; SQUAMOUS-CELL CARCINOMA; PHASE-II TRIAL; TYROSINE KINASE INHIBITOR; UTERINE CERVIX; TUMOR ANGIOGENESIS; CISPLATIN CHEMOTHERAPY; COMBINATION THERAPY; MONOCLONAL-ANTIBODY; UNTREATED PATIENTS;
D O I：
10.1177/1758834014543794
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Patients with advanced stage or recurrent cervical cancer represent a population with limited chemotherapeutic options. More specifically, patients with recurrent disease have a poor salvage rate, with a 5-year survival rate of less than 10%. This year, the first prospective phase III clinical trial exploring the anti-angiogenic agent, bevacizumab, was published, meeting its primary endpoint, with a significant improvement in overall survival. As such, a review of anti-angiogenic therapy in the treatment of this disease is warranted.
引用
收藏
页码：280 / 292
页数：13
相关论文
共 86 条
[1]  
[Anonymous], LANCET ONCOL
[2]   AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients [J].
Batchelor, Tracy T. ;
Sorensen, A. Gregory ;
di Tomaso, Emmanuelle ;
Zhang, Wei-Ting ;
Duda, Dan G. ;
Cohen, Kenneth S. ;
Kozak, Kevin R. ;
Cahill, Daniel P. ;
Chen, Poe-Jou ;
Zhu, Mingwang ;
Ancukiewicz, Marek ;
Mrugala, Maciej M. ;
Plotkin, Scott ;
Drappatz, Jan ;
Louis, David N. ;
Ivy, Percy ;
Scadden, David T. ;
Benner, Thomas ;
Loeffler, Jay S. ;
Wen, Patrick Y. ;
Jain, Rakesh K. .
CANCER CELL, 2007, 11 (01) :83-95
[3]  
Benjamin LE, 1998, DEVELOPMENT, V125, P1591
[4]   Phase I trial of combretastatin A-4 phosphate with carboplatin [J].
Bilenker, JH ;
Flaherty, KT ;
Rosen, M ;
Davis, L ;
Gallagher, M ;
Stevenson, JP ;
Sun, WJ ;
Vaughn, D ;
Giantonio, B ;
Zimmer, R ;
Schnall, M ;
O'Dwyer, PJ .
CLINICAL CANCER RESEARCH, 2005, 11 (04) :1527-1533
[5]   Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: A gynecologic oncology group study [J].
Bloss, JD ;
Blessing, JA ;
Behrens, BC ;
Mannel, RS ;
Rader, JS ;
Sood, AK ;
Markman, M ;
Benda, J .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (07) :1832-1837
[6]   Topotecan in squamous cell carcinoma of the cervix: A phase II study of the gynecologic oncology group [J].
Bookman, MA ;
Blessing, JA ;
Hanjani, P ;
Herzog, TJ ;
Andersen, WA .
GYNECOLOGIC ONCOLOGY, 2000, 77 (03) :446-449
[7]  
Borgström P, 1998, PROSTATE, V35, P1
[8]  
Borgström P, 1999, ANTICANCER RES, V19, P4203
[9]  
Borgstrom P, 1996, CANCER RES, V56, P4032
[10]   Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival [J].
Broglio, Kristine R. ;
Berry, Donald A. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (23) :1642-1649
123456789